References
- KleinRKleinBEKKnudtsonMDPrevalence of age-related macular degeneration in 4 racial/ethnic groups in the multi-ethnic study of atherosclerosisOphthalmology2006113337338016513455
- D’AmicoDJDiseases of the retinaN Engl J Med19943312951068208273
- RosenfeldPJBrownDMHeierJSRanibizumab for neovascular age-related macular degenerationN Engl J Med2006355141419143117021318
- HeierJSBrownDMChongVIntravitreal aflibercept (VEGF trap-eye) in wet age-related macular degenerationOphthalmology2012119122537254823084240
- NitaMGrzybowskiAAscasoFJHuervaVAge-related macular degeneration in the aspect of chronic low-grade inflammation (pathophysiological parainflammation)Mediators Inflamm2014201493067125214719
- LinTWalkerGBKurjiKParainflammation associated with advanced glycation endproduct stimulation of RPE in vitro: implications for age-related degenerative diseases of the eyeCytokine201362336938123601964
- SemeraroFRussoADelcassiLTreatment of exudative age-related macular degeneration with ranibizumab combined with ketorolac eyedrops or photodynamic therapyRetina20153581547155425784358
- RussoACostagliolaCDelcassiLRomanoMRSemeraroFA randomised controlled trial of ranibizumab with and without ketorolac eyedrops for exudative age-related macular degenerationBr J Ophthalmol201397101273127623873901
- GomiFSawaMTsujikawaMNishidaKTopical bromfenac as an adjunctive treatment with intravitreal ranibizumab for exudative age-related macular degenerationRetina20123291804181022718152
- RussoAMorescalchiFVezzoliSReduction of vitreous prostaglandin E2 levels after topical administration of indomethacin 0.5%, bromfenac 0.09%, and nepafenac 0.1Retina Phila Pa201636612271231
- KimSJTomaHSInhibition of choroidal neovascularization by intravitreal ketorolacArch Ophthalmol2010128559620457981
- SchoenbergerSDKimSJNonsteroidal anti-inflammatory drugs for retinal diseaseInt J Inflamm2013201318
- FlaxelCSchainMBHamonSCFrancisPJProspective randomized controlled trial of combination ranibizumab (Lucentis) and bromfenac (Xibrom) for neovascular age-related macular degeneration: a pilot studyRetina201232341742321862953
- SchoenbergerSDKimSJShengJCalcuttMWReduction of vitreous prostaglandin E2 levels after topical administration of ketorolac 0.45%JAMA Ophthalmol2014132215015424264034
- SchoenbergerSDKimSJShahRShengJCherneyEReduction of interleukin 8 and platelet-derived growth factor levels by topical ketorolac, 0.45%, in patients with diabetic retinopathyJAMA Ophthalmol20141321323724336915
- ChenEBenzMSFishRHUse of nepafenac (Nevanac) in combination with intravitreal anti-VEGF agents in the treatment of recalcitrant exudative macular degeneration requiring monthly injectionsClin Ophthalmol201041249125221151329
- ErieJCBarkmeierAJHodgeDOMahrMAHigh variation of intravitreal injection rates and medicare anti-vascular endothelial growth factor payments per injection in the United StatesOphthalmology201612361257126226976701
- RofaghaSBhisitkulRBBoyerDSSaddaSRZhangKSEVEN-UP Study GroupSeven-year outcomes in ranibizumab-treated patients in ANCHOR, MARINA, and HORIZON: a multicenter cohort study (SEVEN-UP)Ophthalmology2013120112292229923642856